A carregar...
Rituximab Biosimilar Prevents Poor Outcomes of Microscopic Polyangiitis and Granulomatosis with Polyangiitis as Effectively as Rituximab Originator
PURPOSE: There has been no extensive study to compare the efficacy between rituximab originator (Mabthera®) and its biosimilar (Truxima®) for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Here, we investigated the clinical effects of rituximab on poor outcomes of MPA and...
Na minha lista:
| Publicado no: | Yonsei Med J |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Yonsei University College of Medicine
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7393299/ https://ncbi.nlm.nih.gov/pubmed/32734735 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3349/ymj.2020.61.8.712 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|